Identifying a Novel DPYD Polymorphism Associated with Severe Toxicity to 5-FU Chemotherapy in a Saudi Patient
Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report a 65-year-old female with rectal adenocarcinoma who experienced severe toxicities secondary to standard dose 5-FU based chemotherapy. She was found to be heter...
Saved in:
Main Authors: | Nedal Bukhari, Faisal Azam, Mohammed Alfawaz, Mohammed Zahrani |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-01-01
|
Series: | Case Reports in Genetics |
Online Access: | http://dx.doi.org/10.1155/2019/5150725 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
by: Qiang Li, et al.
Published: (2014-01-01) -
Retracted: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis
by: Gastroenterology Research and Practice
Published: (2020-01-01) -
TS Gene Polymorphisms Are Not Good Markers of Response to 5-FU Therapy in Stage III Colon Cancer Patients
by: A. Fariña-Sarasqueta, et al.
Published: (2010-01-01) -
Update on the Treatment of Metastatic Urothelial Carcinoma
by: Nedal Bukhari, et al.
Published: (2018-01-01) -
Immediate Response to Chemotherapy in an Adult Neuroblastoma Patient Presenting with Cord Compression
by: Nedal Bukhari, et al.
Published: (2020-01-01)